FI107159B - Menetelmä askomysiinimakrolidijohdannaisten valmistamiseksi - Google Patents

Menetelmä askomysiinimakrolidijohdannaisten valmistamiseksi Download PDF

Info

Publication number
FI107159B
FI107159B FI942444A FI942444A FI107159B FI 107159 B FI107159 B FI 107159B FI 942444 A FI942444 A FI 942444A FI 942444 A FI942444 A FI 942444A FI 107159 B FI107159 B FI 107159B
Authority
FI
Finland
Prior art keywords
formula
hydroxy
compound
och
substituents
Prior art date
Application number
FI942444A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI942444A (fi
FI942444A0 (fi
Inventor
A R C Murty Bulusu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939310969A external-priority patent/GB9310969D0/en
Priority claimed from GB939310975A external-priority patent/GB9310975D0/en
Priority claimed from GB939312590A external-priority patent/GB9312590D0/en
Priority claimed from GB939313553A external-priority patent/GB9313553D0/en
Priority claimed from GB939319618A external-priority patent/GB9319618D0/en
Priority claimed from GB939319617A external-priority patent/GB9319617D0/en
Priority claimed from GB939326045A external-priority patent/GB9326045D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of FI942444A0 publication Critical patent/FI942444A0/fi
Publication of FI942444A publication Critical patent/FI942444A/fi
Application granted granted Critical
Publication of FI107159B publication Critical patent/FI107159B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Color Printing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Seasonings (AREA)
FI942444A 1993-05-27 1994-05-25 Menetelmä askomysiinimakrolidijohdannaisten valmistamiseksi FI107159B (fi)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
GB9310969 1993-05-27
GB939310969A GB9310969D0 (en) 1993-05-27 1993-05-27 Organic compounds
GB9310975 1993-05-27
GB939310975A GB9310975D0 (en) 1993-05-27 1993-05-27 Organic compounds
GB9312590 1993-06-18
GB939312590A GB9312590D0 (en) 1993-06-18 1993-06-18 Organic compounds
GB9313553 1993-07-01
GB939313553A GB9313553D0 (en) 1993-07-01 1993-07-01 Organic compounds
GB939319618A GB9319618D0 (en) 1993-09-23 1993-09-23 Organic compounds
GB9319618 1993-09-23
GB939319617A GB9319617D0 (en) 1993-09-23 1993-09-23 Organic compounds
GB9319617 1993-09-23
GB939326045A GB9326045D0 (en) 1993-12-21 1993-12-21 Organic compounds
GB9326045 1993-12-21

Publications (3)

Publication Number Publication Date
FI942444A0 FI942444A0 (fi) 1994-05-25
FI942444A FI942444A (fi) 1994-11-28
FI107159B true FI107159B (fi) 2001-06-15

Family

ID=27562893

Family Applications (1)

Application Number Title Priority Date Filing Date
FI942444A FI107159B (fi) 1993-05-27 1994-05-25 Menetelmä askomysiinimakrolidijohdannaisten valmistamiseksi

Country Status (24)

Country Link
US (1) US5493019A (zh)
EP (1) EP0626385B1 (zh)
JP (1) JP3076724B2 (zh)
CN (1) CN1048495C (zh)
AT (1) ATE252105T1 (zh)
AU (1) AU682499B2 (zh)
CA (1) CA2124260C (zh)
CY (1) CY2523B1 (zh)
CZ (1) CZ286157B6 (zh)
DE (1) DE69433234T2 (zh)
DK (1) DK0626385T3 (zh)
ES (1) ES2208651T3 (zh)
FI (1) FI107159B (zh)
HK (1) HK1011684A1 (zh)
HU (1) HU218919B (zh)
IL (1) IL109775A (zh)
MY (1) MY110603A (zh)
NO (1) NO308302B1 (zh)
NZ (1) NZ260596A (zh)
PH (1) PH30420A (zh)
PT (1) PT626385E (zh)
RU (1) RU2130460C1 (zh)
SI (1) SI0626385T1 (zh)
SK (1) SK281541B6 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2308546B (en) 1994-10-26 1999-06-02 Novartis Ag Topical macrolide compositions
WO1999019471A1 (en) 1997-10-16 1999-04-22 Board Of Regents, The University Of Texas System Models and treatments for cardiac hypertrophy in relation with nf-at3 function
DK2198858T3 (da) 1998-03-26 2011-10-03 Astellas Pharma Inc Præparat med opretholdt frigivelse af en makrolidforbindelse såsom tacrolimus
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US6121257A (en) * 1999-03-31 2000-09-19 Abbott Laboratories Sulfamate containing macrocyclic immunomodulators
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
CN101897662B (zh) 2002-07-23 2013-05-22 诺瓦提斯公司 包含药物、软膏基质和增溶剂/分散剂的眼用软膏剂组合物
WO2005063242A1 (en) * 2003-12-30 2005-07-14 Astellas Pharma Inc. Use of macrolides for treating or preventing airflow obstruction
GT200500282A (es) 2004-10-12 2006-05-04 Heteroatomos conteniendo compuestos triciclicos.
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
BR112012000750B1 (pt) * 2009-07-15 2021-05-25 Cti Biopharma Corp. sal citrato cristalino, composição farmacêutica compreendendo o referido sal e uso do mesmo
CN107106588B (zh) 2014-10-28 2020-08-11 山口晃史 用于改善妊娠状态的药剂及其使用
JP7465806B2 (ja) 2018-08-10 2024-04-11 晃史 山口 母体と胎児との関係における液性免疫関連疾患の治療薬
CN113226331A (zh) 2018-12-18 2021-08-06 山口晃史 用于改善不孕不育症或妊娠状态的药物
EP3914599A4 (en) * 2019-01-23 2022-10-19 The Johns Hopkins University NON-IMMUNOSUPPRESSIVE ANALOGS OF FK506 AND ASSOCIATED USE
US20230094227A1 (en) * 2020-12-24 2023-03-30 Seoul National University R&Db Foundation Novel fk506 derivative and composition comprising same for promoting hair growth

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0078235A3 (de) * 1981-10-23 1983-06-29 Ciba-Geigy Ag Dihalogenierte Steroide
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
PH26083A (en) * 1987-11-09 1992-02-06 Sandoz Ltd 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof
EP0385936A1 (de) * 1989-02-27 1990-09-05 Ciba-Geigy Ag Peptidlacton und derivate davon, Verfahren zu ihrer Herstellung und Mittel zur Ausführung des Verfahrens
WO1991013889A1 (en) * 1990-03-13 1991-09-19 Fisons Plc Immunosuppressive macrocyclic compounds
CA2051872A1 (en) * 1990-09-24 1992-03-25 Kevin M. Byrne Directed biosynthesis process for prolyl-immunomycin
GB2249787A (en) * 1990-11-19 1992-05-20 Fujisawa Pharmaceutical Co Lactone compounds
WO1992013862A1 (en) * 1991-02-05 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Lactone compounds
JP3036923B2 (ja) * 1991-10-28 2000-04-24 理化学研究所 デプシペプチドａ、ｂその製造方法、並びに抗ウイルス剤及び抗菌剤
HUT66531A (en) * 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them

Also Published As

Publication number Publication date
AU682499B2 (en) 1997-10-09
CA2124260C (en) 2007-04-17
FI942444A (fi) 1994-11-28
JP3076724B2 (ja) 2000-08-14
NO308302B1 (no) 2000-08-28
PT626385E (pt) 2004-03-31
CZ286157B6 (cs) 2000-01-12
MY110603A (en) 1998-08-29
NO941936D0 (no) 1994-05-25
HUT71396A (en) 1995-11-28
DE69433234D1 (de) 2003-11-20
EP0626385A1 (en) 1994-11-30
SI0626385T1 (en) 2004-02-29
ES2208651T3 (es) 2004-06-16
ATE252105T1 (de) 2003-11-15
IL109775A0 (en) 1994-08-26
NZ260596A (en) 1995-10-26
DK0626385T3 (da) 2004-02-16
HU9401582D0 (en) 1994-08-29
FI942444A0 (fi) 1994-05-25
HU218919B (hu) 2000-12-28
CA2124260A1 (en) 1994-11-28
HK1011684A1 (en) 1999-07-16
NO941936L (no) 1994-11-28
DE69433234T2 (de) 2004-08-05
EP0626385B1 (en) 2003-10-15
PH30420A (en) 1997-05-09
US5493019A (en) 1996-02-20
SK281541B6 (sk) 2001-04-09
JPH06340672A (ja) 1994-12-13
SK61194A3 (en) 1995-02-08
CY2523B1 (en) 2006-02-08
CN1048495C (zh) 2000-01-19
CZ129594A3 (en) 1995-01-18
IL109775A (en) 1999-07-14
AU6331794A (en) 1994-12-01
RU2130460C1 (ru) 1999-05-20
CN1099756A (zh) 1995-03-08

Similar Documents

Publication Publication Date Title
FI107159B (fi) Menetelmä askomysiinimakrolidijohdannaisten valmistamiseksi
JP3725901B2 (ja) ラパマイシンヒドロキシエステル、それらの製造方法、および、それらを含有する医薬組成物
US5373014A (en) Rapamycin oximes
US5387680A (en) C-22 ring stabilized rapamycin derivatives
US5484790A (en) Carbamates of rapamycin
KR100351222B1 (ko) 매크로사이클릭 면역 조절제 및 이의 제조방법
US7342011B2 (en) Rifamycin analogs and uses thereof
EP0613901A2 (en) Macrocyclic immunomodulators
CA2405593C (en) Macrolides
HU211135A9 (en) Heteroatoms-containing tricyclic compounds
JP2002540209A (ja) スルファメート含有大環状免疫調節剤
KR100317009B1 (ko) 테트라하이드로피란유도체
JP2562001B2 (ja) マクロライド系抗生物質の２−アミノ糖誘導体
JP2563080B2 (ja) マクロライドの糖誘導体
AU679854C (en) Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them
PL176409B1 (pl) Pochodne tetrahydropiranu, sposób ich wytwarzania i zawierająca je kompozycja farmaceutyczna
MXPA01009935A (es) Inmunomoduladores macorciclicos que contienen fosfato.

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

MM Patent lapsed